2022 Neurotech Leaders Forum
November 7-8, 2022
Embassy Suites, San Francisco Airport Waterfront and Zoom
Tentative Agenda (all times PST)
Day One
8:00-8:30 |
Registration and Coffee |
8:30-9:15 |
State of the Neurotechnology Industry: 2022James Cavuoto, Editor and Publisher, Neurotech ReportsNeurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occurred over the years, the most significant events of the last year, and challenges confronting the industry in years ahead. |
9:15-10:00 |
Keynote AddressMudit Jain, Ph.D., General Partner, Treo Ventures |
10:00-10:30 |
Refreshment Break |
10:30-11:15 |
Neurotech Investment Outlook: Is the Gold Rush Over?Jeremy Koff, Senior Consulting Editor, Neurotech Reports, ModeratorAriane Tom, Ph.D., Managing Director, Kaleida CapitalSuraj Mudichintala, Senior Associate, Action Potential Venture CapitalAmy Kruse, Ph.D., General Partner, Prime Movers LabNick Langhals, Ph.D., Program Director for Translational Devices Programs, National Institutes of Health/NINDSIn the last few years, we've seen a considerable amount of VC investment in neurotech startups. But what will be the effect of more uncertain economic conditions? Our panel of investment professionals will offer their insights. |
11:15-12:00 |
DBS Goes Deep: New Indications Emerge for Neuromodulation TherapiesJennifer French, Senior Contributing Editor, Neurotech Reports, ModeratorLothar Krinke, Ph.D., CEO, Newronika SpaErika Ross, Ph.D., Director, Clinical & Applied Research, Abbott NeuromodulationJacob Robinson, Ph.D., Co-Founder and CEO, Motif NeurotechOnce restricted to treating movement disorders such as Parkinson's disease, deep-brain stimulation now stands to penetrate a range of new disorders. Abbott's reentry in the depression market sends a strong signal that DBS will be a key therapy for treating psychiatric disorders. Our panel of experts will discuss the possibilities. |
12:00-1:30 |
Luncheon, Sponsored by Cirtec Medical |
1:30-3:00 |
Neurotechnology Entrepreneur PanelJames Cavuoto, Editor, Neurotech Reports, ModeratorByoung Kwan Kim, CEO, gBrainLuca Ravagnan, Ph.D., CEO, WISE SrlIngrid van Welie, Ph.D., CEO, Neural Dynamics TechnologiesPerry Teevens, Ph.D., CEO and Co-Founder, REVAIKrishnan Chakravarthy, M.D., Ph.D., Founder and CEO, NXTStimThis session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets. |
3:00-3:30 |
Refreshment Break |
3:30-4:15 |
Sacred Ground: Privacy, Security, and Ethics in NeurotechJo Jo Platt, Contributing Editor, Neurotech Reports, ModeratorMarcus Gerhardt, CEO, Blackrock NeurotechRob Barnes, Principal Consultant, Amazon Web ServicesAnna Wexler, Assistant Professor, Medical Ethics and Health Policy, University of Pennsylvania School of MedicineThis panel features a roundtable discussion to help investors evaluate a technology, founders to learn what's expected, and developers to understand the considerations that need to be baked in to every device. |
4:15-5:00 |
Overcoming Bias: Neurotech Therapies Seek to Penetrate Pharma MarketsJames Cavuoto, Editor, Neurotech Reports, ModeratorMarco Sorani, Ph.D., Executive Director, Development Sciences, Genentech, Inc.Eric Hsu, Partner, Wilson SonsiniVictor Pikov, Ph.D., CEO, Medipace, Inc.The recent controversy surrounding failed drug trials for Alzheimer's and the dubious claims of the amyloid hypothesis highlights some of the bias neuromodulation vendors have had to confront when trying to penetrate a market dominated by big pharma. In this session, we'll explore some of the strategies device firms can employ to overcome the inherent bias that still exists. |
5:00-7:00 |
Cocktail Reception, Sponsored by MST |
Day Two
8:00:8:30 |
Registration and Coffee |
8:30-9:15 |
Facing the Public: An Editorial PerspectiveJames Cavuoto, Editor and Publisher, Neurotech Reports, ModeratorJeremy Koff, Senior Consulting Editor, Neurotech ReportsJo Jo Platt, Contributing Editor, Neurotech ReportsIn this session, Neurotech Reports team of editors will offer their views on recent controversies facing the neuromodulation industry, including ethical concerns, dealing with bad press, and legislative and regulatory developments. |
9:15-10:00 |
Using Our Head: Wearable Brain Devices Exploit New Market OpportunityThe market for noninvasive brain sensing and brain stimulation headsets is poised for growth as users and clinicians seek to exploit expanded knowledge of neural circuits and targets. In this session, three vendors of wearable headsets will describe their technology and market opportunity.Richard Hanbury, CEO and Founder, Sana HealthIain McIntyre, Head of Marketing, Roga LifeIsrael Gasperin, CEO and Founder, Zentrela, Inc. |
10:00-10:30 |
Coffee Break |
10:30-11:15 |
Reimbursement Outlook: CMS Opens the Door for Neurotech TherapiesJeremy Koff, Senior Consulting Editor, Neurotech Reports, ModeratorJames Makous, Ph.D., Principal, Makous Research, LLCChris Hanna, CEO, Pacific Therapy AccessAfter a disappointing decision to repeal the Medicare Coverage of Innovative Technology program, CMS has offered guidance on constructing a replacement that would achieve similar results. And the several new codes for implanted and noninvasive therapies have emerged to help shorten the commercialization path for neurotech startups. Our panel of experts will discuss the reimbursement outlook for neurotech in this session. |
11:15-12:00 |
Fixing What's Broke: Neurorehabilitation Devices Reach the MarketJo Jo Platt, Contributing Editor, Neurotech Reports, ModeratorJeremiah Robison, Founder and CEO, CionicRichard Foust, CEO, MicroTransponder, Inc.Jennifer French, Executive Director, Neurotech NetworkWhen the FDA approved MicroTransponder's Vivistim stroke therapy last year, it ended the drought that followed the Northstar EVEREST trial failure in 2009. In this panel, we'll examine some of the many new implantable and wearable neurorehabilitation therapies reaching the market. |
12:00-1:30 |
Luncheon, Sponsored by Cirtec MedicalPresentation of 2022 Gold Electrode Awards |
1:30-3:00 |
Neurotechnology Entrepreneur PanelJames Cavuoto, Editor, Neurotech Reports, ModeratorYi-Kai Lo, Ph.D., CEO, AneuvoColin Kealey, M.D., President, NeuroSigmaNader Yaghoubi, M.D., Ph.D., President and CEO, PathMaker Neurosystems Inc.Aswin Gunasekar, CEO and Founder, Zeto Inc. |
3:00-3:30 |
Refreshment Break |
3:30-4:15 |
Reinventing the Wheel: Neurotech Startups Outsource Key ComponentsJames Cavuoto, Editor, Neurotech Reports, ModeratorAndrew Kelly, Director of Applications Engineering, Cirtec MedicalHannah Claridge, Ph.D., Head of Neurotechnology, The Technology Partnership plcPeter Putnam, Regional Manager, Micro Systems Technologies, Inc.Neurotech startups can save a considerable amount of time and expense by taking advantage of suppliers of key components such as power sources, interconnects, enclosures, and leads. In this session, we'll discuss the tradeoffs that entrepreneurs and their investors confront when making build or buy decisions. |
4:15-5:00 |
Spreading the Pain: Neuromodulation Vendors Stake Out New GroundJeremy Koff, Senior Consulting Editor, Neurotech Reports, ModeratorManfred Franke, Ph.D., CEO, Neuronoff Inc.Ramana Naidu, M.D., Pain Physician and Anesthesiologist, California Orthopedics and SpineDevjani Saha, Ph.D., Director, Neurology Regulatory Affairs, MCRAThe market for treating chronic pain continues to be the largest segment of the neuromodulation industry, but vendors of SCS, PNS, and noninvasive devices are offering numerous therapeutic options for treating different types of pain. In this session, we'll explore the outlook for new targets and stimulation regimens. |
5:00-7:00 |
Cocktail Reception, Sponsored by MST |